Effect of Co-enzyme Q10 on the Bone Volume of Alveolar Cleft Reconstruction

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

12 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-15

Study Completion Date

2026-04-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Evaluate the effect of Co-enzyme Q10 on the bone volume in unilateral alveolar cleft repair

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Combination of Bone Marrow Concentrate and Iliac Cancellous Bone Graft in Alveolar Cleft Grafting

NCT04414423

Alveolar Cleft Grafting

COMPLETED NA

Tissue Engineered Constructs for Alveolar Cleft Repair

NCT03563495

Cleft Lip and Palate

COMPLETED NA

Assessment of Bone Quality and Quantity for Three Dimensional Bone Augmentation for Maxilla Using Patient Specific Titanium Meshes Loaded With Bone Marrow Aspirate Mixed With Xenograft Versus Xenograft Mixed With Autografts Only: a Randomized Clinical Trial

NCT05400044

Atrophic Maxilla

UNKNOWN NA

Sticky Bone Grafting With Concentrated Growth Factor Membrane for Repair of Unilateral Alveolar Cleft

NCT07066293

Unilateral Alveolar Cleft of Maxilla

COMPLETED NA

Evaluation of Computer-Guided Secondary Alveolar Cleft Bone Grafting With and Without Platelet-Rich Fibrin

NCT05422196

Alveolar Bone Grafting

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Cleft lip or palate is the most frequent congenital abnormality, accounting for about 0.3/1000 live births in Egypt and 1/ 500-1000 live births worldwide. In 75% of patients, cleft lip and palate are accompanied by an alveolar cleft. Alveolar cleft reconstruction is needed to conserve the continuity of the arch, provide the maximum amount of bone support for the nose and permanent teeth eruption, and repair the residual oro-antral fistula. Alveolar cleft grafting is performed at various ages, but secondary grafting, performed between the ages of 9 and 12, is the most suitable and advantageous. Due to its osteogenic, osteoinductive, and osteoconductive properties, the autogenous iliac bone graft is considered the "gold standard" for alveolar cleft repair. However, the autogenous iliac bone graft is associated with a graft resorption rate of about 15-24% during the first six months. In order to resolve those complications, different substances were combined with the iliac graft, such as platelet-rich plasma (PRP), fibrin glue, or bone morphogenic protein (BMP). Nevertheless, it was demonstrated that there was no difference between iliac grafts with or without these materials. Various graft materials, such as allograft, xenograft, and synthetic bone grafts, have been utilized as an alternative to autogenous bone grafts. Allografts are expensive and associated with risks of bacterial contamination, viral transmission, and immunogenicity. Conversely, the main drawbacks of synthetic bone grafts are slow resorption and brittleness. A combination of hydroxyapatite and b-tricalcium phosphate, along with an autogenous bone graft, has been used to address these drawbacks. Co-enzyme Q10 is a lipid-soluble vitamin-like compound present in the inner membrane of the mitochondria of every cell of the body. The structure of Coenzyme Q10 consists of a benzoquinone ring and a lipophilic isoprenoid side chain with ten isoprenyl units in the case of humans, which determines its low polarity and allows its fast diffusion through mitochondrial membrane. Recently, Coenzyme Q10 has gained attention for its therapeutic application for several disorders including cardiovascular diseases, inflammation, human fertility, and diabetes mellitus. Co-enzyme Q10 provides membrane stabilizing properties and acts as an antioxidant with cell-protective effect which acts as an inhibitor of RANKLinduced osteoclast differentiation and enhancer of bone-forming osteoblast differentiation. Co-enzyme Q10 leads to a decreased TRAP+ MNCs formation, as well as dose-dependent down regulation of gene expressions, NFATc1, TRAP, and OSCAR, for osteoclast differentiation. Co-enzyme Q10 in high concentrations (over 10 µM) disturbed the production of ROS and attenuates the H2O2-induced early signaling activities including p38, IκBα, and JNK signaling pathways. Additionally, Co-enzyme Q10 furthered the induction of osteoblastogenic gene markers and also promoted matrix mineralization by enhancing bone nodule formation. Co-enzyme Q10 treatment is safe, even at the highest doses. Most clinical trials have not reported significant adverse effects that necessitated stopping therapy. It undergoes biotransformation in the liver and is eliminated primarily via the biliary tract; therefore it can accumulate in patients with hepatic impairment or biliary obstruction. Many studies used Co-enzyme Q10 in bone augmentation and socket preservation. The use of Co-enzyme Q10 enhances the bone quality and decreases the rate of bone resorption. No study has investigated the effect of the Co-enzyme Q10 in the reconstruction of the alveolar cleft, despite its role in bone healing. Consequently, the present study targeted to assess the significance of Co-enzyme Q10 on the quality and quantity of bone formation in unilateral alveolar cleft repair

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Coenzyme Q10 Alveolar Cleft Grafting

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Iliac bone graft

In the control group, A skin incision will be performed 1cm posterior to the anteriorsuperior iliac crest for iliac grafting. External oblique muscle and periosteum will be reflected medially to expose the anterior iliac crest. The cancellous graft will be gathered using trephine burs and surgical curettes after trap door fenestration reflection. The wound will be closed in three layers; muscle, subcutaneous, and skin. The cancellous bone will be packed to fill the alveolar defect in the control group.

Group Type ACTIVE_COMPARATOR

iliac bone graft

Intervention Type PROCEDURE

iliac bone used as a graft for alveolar cleft reconstruction

CoQ10 graft

the Co-enzyme Q10 will be packed into the alveolar cleft defect alone

Group Type ACTIVE_COMPARATOR

Coenzyme Q 10

Intervention Type PROCEDURE

Patients received Coenzyme Q 10 as a graft material in unilateral maxillary alveolar cleft

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Coenzyme Q 10

Patients received Coenzyme Q 10 as a graft material in unilateral maxillary alveolar cleft

Intervention Type PROCEDURE

iliac bone graft

iliac bone used as a graft for alveolar cleft reconstruction

Intervention Type PROCEDURE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* age ranged between 10-14 years, with good oral hygiene and general good health

Exclusion Criteria

* patients with syndromes associated with an alveolar cleft, local pathosis at the maxilla that may interfere with surgery, previous grafting attempts, or cleft palate fistulae

Minimum Eligible Age

10 Years

Maximum Eligible Age

14 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes